Permanent genetic modification (base editing) targeting the PCSK9 gene to drastically reduce LDL cholesterol represents a potential therapeutic revolution, capable of replacing chronic pharmaceutical management with a single, definitive solution.

noli's read

The community is showing cautious but notable enthusiasm for this technology, which is viewed as a major paradigm shift despite the standard uncertainties of clinical development. Scientifically, PCSK9 gene inhibition is a validated strategy already leveraged by monoclonal antibodies and small interfering RNAs (evidence: RCT clinical trials, cardiological consensus). Base editing to 'turn off' this gene is an innovative approach that has shown promising early results in phase 1 studies (Verve Therapeutics), but long-term data on human safety and efficacy are severely lacking. The idea that modifying a gene is risk-free is exaggerated, as every genetic intervention carries risks of off-target effects and unforeseen metabolic consequences over a lifetime, which justifies the need for large-scale clinical studies. It is also important to note that PCSK9 is not responsible for all cholesterol management, and the assertion that this therapy alone would eliminate atherosclerosis is optimistic speculation. The community converges on the idea that this technology is a fascinating advancement, while vigorously debating safety risks and commercial motivations.

the sources

1. 1r/PeterAttia